EMA signs up to AdisInsight on a four-year deal

Drug database AdisInsight provides reliable data for researchers, strategists, regulators and healthcare providers.

The European Medicines Agency (EMA) has signed a four-year agreement with Adis, a leading global provider of drug information, for AdisInsight, a database for drug research and development, disease treatment and decision making. Adis is part of the leading global scientific, technical and medical publisher Springer.

Mike Sumner, Director of Product Management for AdisInsight at Adis, said:

“This is a landmark deal for AdisInsight as it demonstrates that we can deliver a first-rate experience for users of drug databases. EMA is a very important customer and their commitment to a four-year license is a strong endorsement of the improvements we have made with the new platform. We are very happy to be continuing our relationship with them over the coming years.”

Based on trusted, scientifically sound data, AdisInsight brings together essential information on drugs in commercial development, key clinical trials, deals undertaken and safety profiles, in one database, available for preview at adisinsight.springer.com.

EMA announced earlier this year that they were seeking a comprehensive drug database to provide scientific, economic and industry-related information. Although EMA had been using the old Adis databases for two years, the publisher was required to submit a new tender as part of the Agency’s procurement process. Database users within the Agency will now begin integrating the new AdisInsight platform into their workflows with support from the AdisInsight product experts who will be on hand to deliver training and guidance.

The European Medicines Agency (EMA) is a decentralized agency of the European Union, located in London. The EMA’s main responsibility is the protection and promotion of public and animal health, through the evaluation and supervision of medicines for human and veterinary use.

Adis offers a reputable and independent portfolio of medical journals and business intelligence solutions for healthcare professionals, researchers, decision makers and drug developers. AdisInsight presents a unique, joined-up view of current evidence on drug treatments being developed worldwide – how well they work, how safe they are, who is working on them, and how soon they will be available – in a single database.

Springer is part of Springer Nature, a leading global research, educational and professional publisher, home to an array of respected and trusted brands providing quality content through a range of innovative products and services. Springer Nature is the world’s largest academic book publisher, publisher of the world’s highest impact journals and a pioneer in the field of open research. The company numbers almost 13,000 staff in over 50 countries and has a turnover of approximately EUR 1.5 billion. Springer Nature was formed in 2015 through the merger of Nature Publishing Group, Palgrave Macmillan, Macmillan Education and Springer Science+Business Media. Find out more: www.springernature.com and follow @SpringerNature

Double-digit growth in Impact Factors for Adis Journals

The Adis Journals team is celebrating the recent publication of the 2014 Journal Citation Reports® which revealed double-digit growth in the Impact Factor for seven of its titles over the previous year.

Of the sixteen Adis Journals currently listed in the reports, eleven saw an increase in this latest announcement. Six journals have Impact Factors that rank in the top quartile of their subject category including Clinical Pharmacokinetics, CNS Drugs, Drug Safety, Drugs, PharmacoEconomics and American Journal of Clinical Dermatology. Two Adis journals now have an Impact Factor above 5; CNS Drugs with an Impact Factor of 5.113, and Clinical Pharmacokinetics with an Impact Factor of 5.053.

cpk_cvr
Clinical Pharmacokinetics

The most significant growth was for BioDrugs, a journal that covers the development and use of biotechnology-based pharmaceuticals and innovative technologies for the treatment of human disease. The journal has a new Impact Factor of 2.989 as a result of an astonishing 41% increase.Other titles achieving substantial improvements include the European Journal of Drug Metabolism and Pharmacokinetics and Targeted Oncology with impressive gains of 19.1% and 15.7% respectively.

The Journal Citation Reports® from Thomson Reuters provide a measure of a journal’s impact, with the Impact Factor representing the number of times an article from each title is cited on average.

Adis is a leading publishing of drug therapy-focused medical journals with a portfolio of over 30 titles. Their journals offer reputable and independent content of interest to anyone involved in medical research, practice or teaching; drug regulation or reimbursement; or those in the pharmaceutical industry.

New AdisInsight platform officially launched

Adis has taken a major step forward in its quest to make expertly-written drug information more accessible, with the launch of a new platform.

AdisInsight presents a unique, joined-up view of current evidence on drug treatments being developed worldwide – how well they work, how safe they are, who is working on them, and how soon they will be available – in a single database.

All of the content in the platform is created as a result of a rigorous curation process undertaken by a team of scientific editors. Multiple global sources including journals, conference proceedings, government and company websites are monitored continuously to identify any potentially relevant new data. Information is then assessed and verified before being consolidated into concise narratives.

Mike Sumner, Director of Product Management for AdisInsight, explains:

“We know that many people access drug information – from academics to regulators, investors to healthcare providers and of course, pharmaceutical manufacturers. These groups may use the information in different ways but they all share a common need – to quickly and easily find accurate data to answer their questions. The AdisInsight platform is designed to help them do just that.”

Adis is a leading global provider of drug information and part of Springer Science+Business Media. For more than 40 years Adis has been supporting its users through its portfolio of drug-focused medical journals and business intelligence solutions. AdisInsight brings together content from three well-established Adis databases – R&D Insight, Clinical Trials Insight and Pharmacovigilance Insight. The AdisInsight platform is available to preview now at adisinsight.springer.com

New Adis platform connects the world of drug development

Adis has unveiled a new platform for drug development and research, disease treatment and decision making, based on its well-established R&D Insight, Clinical Trials Insight and Pharmacovigilance Insight databases.

AdisInsight brings together essential scientific information on drugs in commercial development, key clinical trials, deals undertaken and safety profiles, in one easy-to-use database.

An introduction to AdisInsight 

A methodical approach is followed for creating content for the database, focusing on quality and relevance. A team of scientific editors review, assess and summarize new information from multiple sources including journals, conference proceedings, government and company websites, to ensure that readers have timely access to reliable data.

The platform was designed in response to extensive customer and market research which revealed new insights into the way users search. Mike Sumner, Director of Product Manager for AdisInsight, explained:

“Databases were historically designed to cater to the expert searcher – an individual who knows what they are looking for and how to create complex queries to find it. We understand that users of our content have vastly different needs, and they don’t always know exactly what to search for in order to meet them.  The new database is designed to help people find the answers they need, whether they are an expert searcher, or a casual browser. By making easy to search, we’ve made expertly-written drug information more accessible for everyone.“

Users can now find information from each stage of the drug lifecycle with a single search in AdisInsight, eliminating the need for them to access multiple databases.  For example, searching for a drug will also reveal any related deals, clinical trials or safety reports, which speeds up the research process for users and can help them to make better informed decisions.

AdisInsight is available online now and can be previewed at adisinsight.springer.com. More information can be found at adis.com/AdisInsight.

Adis celebrates 20 years of monitoring drugs in development

The AdisInsight team have recently celebrated a milestone for their drug pipeline database, R&D Insight, which published its first drug profile twenty years ago.

In 1994, the first drug profile was written by Stephanie Irvine, one of the founding members of the editorial team for a new database being launched by Adis. The profile was based on the drug Benidipine, a calcium antagonist developed by Kyowa Hakko for the treatment of essential hypertension and angina pectoris.

Since the profile was first created, the editorial team have continued to track the progress of the drug, building a twenty-year history of its development, including company agreements, pharmacodynamics data, and reports on adverse events and clinical trials. At present, Benidipine is marketed in Japan, Turkey, China and the Philippines (as Coniel®) and India (as Caritec®).

R&D Insight now contains profiles of over 30,000 drugs and covers drug- and cell-based products worldwide, focusing on those in development by industry, or with industry involvement, where the drug will be regulated as a prescription drug or available only to physicians for administration.

Glenn Whiteside, Product Specialist for R&D Insight at Adis remarks

“Our goal has always been to provide our users with the most relevant, scientifically-sound data on drugs in development, and we are really proud of the product that we have built over the last two decades”.

The database has thousands of users globally from pharmaceutical companies to universities, hospitals to financial institutions. To support their wide range of users, Adis is in the process of developing a new platform for its AdisInsight database content, which is due to be launched in 2015.

Mike Sumner, VP for Adis Product Management & Development at Springer, states

“This is a really exciting time for AdisInsight as we work on a new platform that will bring together all of our content on drugs, trials, deals and safety for the first time. I believe that the new AdisInsight will help our users to carry out their research faster, make greater discoveries and really benefit from the scientific expertise behind each record.”

The full profile for Benidipine can be viewed here. For more information about R&D Insight, please visit adis.com.

Adis involved in the First EMR/Arab Countries meeting

Adis was pleased to be involved in a breakthrough pharmacovigilance event hosted by the Centre Anti Poison et de Pharmacovigilance du Maroc (CAPM), which took place on 22-26 September 2014 in Rabat, the capital city of Morocco.

The summit was organized by CAPM in association with the Moroccan Society of Pharmacovigilance (SMPV), the Council for International Organizations of Medical Sciences (CIOMS), the International Society of Pharmacovigilance (ISoP) and Springer.

The purpose of the meeting was to promote interaction, exchange information, implement and reinforce national pharmacovigilance activities in Arabic countries and define an action plan for its development.

Attendees of the meeting

Springer offers a range of products and services in drug safety and pharmacovigilance through the Adis brand, and got involved in the event with a view to understanding the needs of Arab countries when it comes to monitoring the safety of medicines, as well as possibly providing support and resources that may help with building awareness and respond to work and educational needs.

Daniela Ranzani, Product Manager for Pharmacovigilance at Adis, hosted a presentation on the challenges and trends in literature monitoring for pharmacovigilance and stated

“The content presented at this meeting was extremely valuable, as were the working groups that were established for discussion of topics such as integrated pharmacovigilance systems, harmonization of terminology and definitions, risk minimization plans and how to strengthen national pharmacovigilance systems for vaccines. We firmly believe that this was the first milestone in a series of events, whether they are discussion forums or educational workshops, and Springer is ready to engage further with this vital segment , to collaborate with centers in this region, and to provide them with any support and resources they may need.”

The meeting was also attended by Nadja Madani, Springer’s Licensing Manager for Health, Hospitals & Pharma in the region, who commented:

“We were very pleased to participate in the meeting, which had a rich programme including presentations and participation from several regional and international authorities, including the WHO, the US FDA, the Arab League, the Uppsala Monitoring Centre, experts from the Industry, representatives from national drug safety authorities and Health Ministries in the Arab region, amongst others. A special thanks goes to Rachida Soulaymani, Head of the Centre Anti Poison et de Pharmacovigilance du Maroc, for having us and to all of her wonderful staff and participants – we hope to see them all again soon.”

A full meeting report will be published soon in one of the Adis Journals.

Webinar on Adis research and analysis services

Adis will be hosting two free webinar sessions in October to provide an introduction to its range of Custom Intelligence research and analysis solutions.

The Custom Intelligence service enables organizations to employ additional expertise in research and analysis without expanding their headcount. Operating as an extension to existing teams, the Adis team of analysts will work with the organization to understand their research problem, make recommendations on the most suitable approach, and deliver results in the most appropriate format to aid interpretation. The service is used already by clients across many different industries including pharmaceutical and biotech companies, the financial and investment sector, as well academia, charitable organizations, government departments and consultancies.

The team can offer support with a wide variety of research projects, big and small, such as conference coverage, identification of licensing opportunities, visualizations of global clinical development, longitudinal pipeline analyses, and much more.

The webinars will take place on Tuesday, October 21 and Thursday, October 23, and are free for anyone to attend. All that is required is an internet connection and a phone line, to enable you to take part in the discussions.

The sessions will be hosted by Will Stow, Product Specialist for Custom Business Intelligence at Adis, and will provide an overview of the service and its primary data sources. The different kinds of services available will be explained and real-life client-use scenarios will be discussed. Following the discussion there will be time for questions from attendees.

It is recommended that interested parties register for the sessions as early as possible to secure their place, using the links provided below:

Adis has been providing high-quality content focused on the evaluation of drugs and their impact on the therapeutic landscape for over 40 years through its portfolio of leading journals and databases. To find out more visit adis.com

Invitation to contribute to a themed issue of PharmacoEconomics

“Big Data and its Application in Health Economics and Outcomes Research”

We are planning a themed issue of PharmacoEconomics on big data. The purpose of this themed issue is to advance the application of methods and analytics relevant to the use of big data in health economics and outcomes research (HEOR). This issue will become a valuable source of innovative methods and concepts specific to HEOR.

This Call for Papers arose out of the growing international interest in big data and the concurrent recognition that researchers trained in HEOR lack a collective source of papers that tackle emerging concerns for HEOR with regards to the availability of big data. Conceptual papers will discuss best practices, challenges and opportunities for the conduct of HEOR using big data. Applied papers will focus on methods for the analysis of patient-level data or the use of big data in mathematical modeling/simulation. We welcome contributions from diverse fields such as HEOR, operations research, business, finance, computer science, and engineering.

Given the purpose of this theme issue, it is important that the papers present a clear, accessible discussion that would engage researchers unfamiliar with the topic. Applied papers should present material in a way that supports the practical use of the methods among HEOR scientists. Each submitted paper should accomplish the following objectives: 1) place the paper at the intersection of big data and HEOR; 2) provide a well-balanced discussion of the practical implications or applications of their paper; 3) discuss how the paper supports the field of HEOR in harnessing the availability of big data.

Priority will be given to papers that have potential to be of practical use to the HEOR community, decision makers and payers. Papers in any of the following categories will be considered

I. General Overview articles

II. Computing Issues with Big Data

III. Data Quality Issues

IV. Current Analytical Issues

V. Emerging Methods of Analysis

VI. Characteristics of Claims-Based Databases

VII. Addressing Uncertainty

If you would like to contribute to one of these themes, please submit an abstract of up to 400 words by 31st December 2014 to chris.carswell@springer.com. Authors of selected abstracts will be notified by the end of January 2015 and asked to submit their final manuscript by 30th April 2015.
Ebere Onukwugha
Guest Editor

Christopher Carswell
Editor in Chief, PharmacoEconomics

Adis involved in a breakthrough pharmacovigilance summit

Adis is working in partnership with the Centre Anti Poison et de Pharmacovigilance du Maroc to host a special pharmacovigilance event for Arabic-speaking countries.

Adis is pleased to announce its involvement in an upcoming pharmacovigilance event, being hosted by the Centre Anti Poison et de Pharmacovigilance du Maroc (CAPM).

The summit, organized by CAPM in association with the Moroccan Society of Pharmacovigilance (SMPV), the Council for International Organizations of Medical Sciences (CIOMS), and the International Society of Pharmacovigilance (ISoP) will take place on 22-26 September 2014, and it is the first event of its kind in the region.

Morocco was the first Arabic country to join the International Pharmacovigilance Programme lead by WHO, and of the 22 countries belonging to the Arab League, 40% are currently official members. However, Arab countries representation in Vigibase amounts to only 0.4% of all individual case reports.

The purpose of this meeting is to interact, exchange information, implement and reinforce national pharmacovigilance activities in Arabic countries and define an action plan for its development.

Click here to read the first announcement and draft program. To register for the event, complete the registration form here or email the organizers at louammi@gmail.com

Adis celebrates significant gains in 2013 Impact Factor announcement

Adis, a leading publisher of drug-focused medical journals, is celebrating after the 2013 Journal Citation Reports® revealed substantial growth in Impact Factors for a number of its titles.

The most outstanding success was that of Molecular Diagnosis & Therapy, which saw its Impact Factor increase 53% over the year, taking it to 2.589. The journal focuses on molecular diagnostic and pharmacogenomics techniques and their application in the fast-moving field of personalized medicine.

md_cvr
Molecular Diagnosis & Therapy

Other noteworthy results include the American Journal of Clinical Dermatology and The Patient: Patient-Centered Outcomes Research, the Impact Factors of which increased by 37% and 25% respectively.

PharmacoEconomics, a title focusing on the cost-effective use of drug therapy for decision makers, maintained its position as the highest ranked health economics and outcomes research journal with a growth of 17%.

At the beginning of 2014, Adis expanded its journal portfolio to incorporate eleven Adis Rapid+ Journals, formerly known as Springer Healthcare Rapid Publications. The flagship title from this portfolio, Advances in Therapy, has continued to build on previous years’ successes with a further improved Impact Factor of 2.438. Adis also added two Springer journals to its offerings, European Journal of Drug Metabolism and Pharmacokinetics and Targeted Oncology, both of which saw double digit increases in the latest announcement.

The Journal Citation Reports® from Thomson Reuters are a measure of a journal’s impact, representing the number of times an article from each title is cited on average.

Adis has a portfolio of over 30 medical journals and newsletters, offering reputable and independent content of interest to anyone involved in medical research, practice or teaching; drug regulation or reimbursement; or those in the pharmaceutical industry.